Prognostic impact of carbohydrate sulfotransferase 15 in patients with pancreatic ductal adenocarcinoma

Ito,Zensho; Takakura,Kazuki; Suka,Machi; Kanai,Tomoya; Saito,Ryota; Fujioka,Shuichi; Kajihara,Mikio; Yanagisawa,Hiroyuki; Misawa,Takeyuki; Akiba,Tadashi; Koido,Shigeo; Ohkusa,Toshifumi

doi:10.3892/ol.2017.6071

Prognostic impact of carbohydrate sulfotransferase 15 in patients with pancreatic ductal adenocarcinoma

Authors:
- Zensho Ito
- Kazuki Takakura
- Machi Suka
- Tomoya Kanai
- Ryota Saito
- Shuichi Fujioka
- Mikio Kajihara
- Hiroyuki Yanagisawa
- Takeyuki Misawa
- Tadashi Akiba
- Shigeo Koido
- Toshifumi Ohkusa
View Affiliations

Affiliations: Division of Gastroenterology and Hepatology, Department of Internal Medicine, Jikei University School of Medicine, Kashiwa Hospital, Kashiwa, Chiba 277‑8564, Japan, Department of Public Health and Environmental Medicine, Jikei University School of Medicine, Tokyo 105‑8461, Japan, Department of Surgery, Jikei University School of Medicine, Kashiwa Hospital, Kashiwa, Chiba 277‑8564, Japan
Published online on: April 21, 2017 https://doi.org/10.3892/ol.2017.6071
Pages: 4799-4805
Copyright: © Ito et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Patients with pancreatic ductal adenocarcinoma (PDA) typically succumb to mortality early, even following surgical resection. Therefore, prognostic factors associated with early mortality are required to improve the survival of patients with PDA following surgical resection. Carbohydrate sulfotransferase 15 (CHST15) is responsible for the biosynthesis of sulfated chondroitin sulfate E (CS‑E), which serves a pivotal function in cancer progression by cleaving CD44. CHST15 and CD44 expression in PDA tissue were assessed as a prognostic factor in patients with PDA following surgical resection. A total of 36 consecutive patients with PDA were enrolled following surgical resection between January 2008 and December 2014. The intensities of CHST15 and CD44 expression were analyzed by immunohistochemical staining. The recurrence period was significantly earlier in the strong CHST15 expression group compared with the negative‑to‑moderate CHST15 expression group. Overall survival (OS) was also significantly decreased in the strong CHST15 expression group compared with the negative‑to‑moderate CHST15 expression group. Multivariate analysis also indicated significant associations between CHST15 overexpression and disease‑free survival (DFS) and OS. However, expression of CD44 in PDA tissue was not associated with DFS or OS. The present study has demonstrated for the first time that high CHST15 expression in PDA tissue may represent a potential predictive marker of DFS and OS in patients with PDA following surgical resection.

View Figures

View References

1	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
2	Stathis A and Moore MJ: Advanced pancreatic carcinoma: Current treatment and future challenges. Nat Rev Clin Oncol. 7:163–172. 2010. View Article : Google Scholar : PubMed/NCBI
3	Chari ST, Kelly K, Hollingsworth MA, Thayer SP, Ahlquist DA, Andersen DK, Batra SK, Brentnall TA, Canto M, Cleeter DF, et al: Early detection of sporadic pancreatic cancer: Summative review. Pancreas. 44:693–712. 2015. View Article : Google Scholar : PubMed/NCBI
4	Arslan C and Yalcin S: Current and future systemic treatment options in metastatic pancreatic cancer. J Gastrointest Oncol. 5:280–295. 2014.PubMed/NCBI
5	Fischer R, Breidert M, Keck T, Makowiec F, Lohrmann C and Harder J: Early recurrence of pancreatic cancer after resection and during adjuvant chemotherapy. Saudi J Gastroenterol. 18:118–121. 2012. View Article : Google Scholar : PubMed/NCBI
6	Pothacharoen P, Siriaunkgul S, Ong-Chai S, Supabandhu J, Kumja P, Wanaphirak C, Sugahara K, Hardingham T and Kongtawelert P: Raised serum chondroitin sulfate epitope level in ovarian epithelial cancer. J Biochem. 140:517–524. 2006. View Article : Google Scholar : PubMed/NCBI
7	Vallen MJ, Schmidt S, Oosterhof A, Bulten J, Massuger LF and van Kuppevelt TH: Primary ovarian carcinomas and abdominal metastasis contain 4,6-disulfated chondroitin sulfate rich regions, which provide adhesive properties to tumour cells. PLoS One. 9:e1118062014. View Article : Google Scholar : PubMed/NCBI
8	Ricciardelli C, Mayne K, Sykes PJ, Raymond WA, McCaul K, Marshall VR, Tilley WD, Skinner JM and Horsfall DJ: Elevated stromal chondroitin sulfate glycosaminoglycan predicts progression in early-stage prostate cancer. Clin Cancer Res. 3:983–992. 1997.PubMed/NCBI
9	Ricciardelli C, Quinn DI, Raymond WA, McCaul K, Sutherland PD, Stricker PD, Grygiel JJ, Sutherland RL, Marshall VR, Tilley WD and Horsfall DJ: Elevated levels of peritumoral chondroitin sulfate are predictive of poor prognosis in patients treated by radical prostatectomy for early-stage prostate cancer. Cancer Res. 59:2324–2328. 1999.PubMed/NCBI
10	Vallen MJ, van der Steen SC, van Tilborg AA, Massuger LF and van Kuppevelt TH: Sulfated sugars in the extracellular matrix orchestrate ovarian cancer development: ‘when sweet turns sour’. Gynecol Oncol. 135:371–381. 2014. View Article : Google Scholar : PubMed/NCBI
11	van der Steen SC, van Tilborg AA, Vallen MJ, Bulten J, van Kuppevelt TH and Massuger LF: Prognostic significance of highly sulfated chondroitin sulfates in ovarian cancer defined by the single chain antibody GD3A11. Gynecol Oncol. 140:527–536. 2016. View Article : Google Scholar : PubMed/NCBI
12	ten Dam GB, van de Westerlo EM, Purushothaman A, Stan RV, Bulten J, Sweep FC, Massuger LF, Sugahara K and van Kuppevelt TH: Antibody GD3G7 selected against embryonic glycosaminoglycans defines chondroitin sulfate-E domains highly up-regulated in ovarian cancer and involved in vascular endothelial growth factor binding. Am J Pathol. 171:1324–1333. 2007. View Article : Google Scholar : PubMed/NCBI
13	Wegrowski Y and Maquart F: Chondroitin sulfate proteoglycans in tumor progression. Adv Pharmacol. 53:297–321. 2006. View Article : Google Scholar : PubMed/NCBI
14	Mizumoto S, Watanabe M, Yamada S and Sugahara K: Expression of N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase involved in chondroitin sulfate synthesis is responsible for pulmonary metastasis. Biomed Res Int. 2013:6563192013. View Article : Google Scholar : PubMed/NCBI
15	Ohtake S, Ito Y, Fukuta M and Habuchi O: Human N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase cDNA is related to human B cell recombination activating gene-associated gene. J Biol Chem. 276:43894–43900. 2001. View Article : Google Scholar : PubMed/NCBI
16	Takakura K, Shibazaki Y, Yoneyama H, Fujii M, Hashiguchi T, Ito Z, Kajihara M, Misawa T, Homma S, Ohkusa T and Koido S: Inhibition of cell proliferation and growth of pancreatic cancer by silencing of carbohydrate sulfotransferase 15 in vitro and in a Xenograft model. PLoS One. 10:e01429812015. View Article : Google Scholar : PubMed/NCBI
17	Sugahara KN, Hirata T, Tanaka T, Ogino S, Takeda M, Terasawa H, Shimada I, Tamura J, ten Dam GB, van Kuppevelt TH and Miyasaka M: Chondroitin sulfate E fragments enhance CD44 cleavage and CD44-dependent motility in tumor cells. Cancer Res. 68:7191–7199. 2008. View Article : Google Scholar : PubMed/NCBI
18	Thomas L, Byers HR, Vink J and Stamenkovic I: CD44H regulates tumor cell migration on hyaluronate-coated substrate. J Cell Biol. 118:971–977. 1992. View Article : Google Scholar : PubMed/NCBI
19	Günthert AR, Sträter J, von Reyher U, Henne C, Joos S, Koretz K, Moldenhauer G, Krammer PH and Möller P: Early detachment of colon carcinoma cells during CD95 (APO-1/Fas)-mediated apoptosis. I. De-adhesion from hyaluronate by shedding of CD44. J Cell Biol. 134:1089–1096. 1996. View Article : Google Scholar : PubMed/NCBI
20	Goebeler M, Kaufmann D, Bröcker EB and Klein CE: Migration of highly aggressive melanoma cells on hyaluronic acid is associated with functional changes, increased turnover and shedding of CD44 receptors. J Cell Sci. 109:1957–1964. 1996.PubMed/NCBI
21	Hirata K, Suzuki H, Imaeda H, Matsuzaki J, Tsugawa H, Nagano O, Asakura K, Saya H and Hibi T: CD44 variant 9 expression in primary early gastric cancer as a predictive marker for recurrence. Br J Cancer. 109:379–386. 2013. View Article : Google Scholar : PubMed/NCBI
22	Cho Y, Lee HW, Kang HG, Kim HY, Kim SJ and Chun KH: Cleaved CD44 intracellular domain supports activation of stemness factors and promotes tumorigenesis of breast cancer. Oncotarget. 6:8709–8721. 2015. View Article : Google Scholar : PubMed/NCBI
23	Yang JJ, Hu ZG, Shi WX, Deng T, He SQ and Yuan SG: Prognostic significance of neutrophil to lymphocyte ratio in pancreatic cancer: A meta-analysis. World J Gastroenterol. 21:2807–2815. 2015. View Article : Google Scholar : PubMed/NCBI
24	Takakura K, Ito Z, Suka M, Kanai T, Matsumoto Y, Odahara S, Matsudaira H, Haruki K, Fujiwara Y, Saito R, et al: Comprehensive assessment of the prognosis of pancreatic cancer: Peripheral blood neutrophil-lymphocyte ratio and immunohistochemical analyses of the tumour site. Scand J Gastroenterol. 51:610–617. 2016. View Article : Google Scholar : PubMed/NCBI
25	Edge SB and Compton CC: The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surgi Oncol. 17:1471–1474. 2010. View Article : Google Scholar
26	Metindir J, Dilek GB and Pak I: Staining characterization by immunohistochemistry of tumor cancer antigen in patients with endometrial cancer. Eur J Gynaecol Oncol. 29:489–492. 2008.PubMed/NCBI
27	Lara MF, González-González E, Speaker TJ, Hickerson RP, Leake D, Milstone LM, Contag CH and Kaspar RL: Inhibition of CD44 gene expression in human skin models, using self-delivery short interfering RNA administered by dissolvable microneedle arrays. Hum Gene Ther. 23:816–823. 2012. View Article : Google Scholar : PubMed/NCBI
28	Kugelman LC, Ganguly S, Haggerty JG, Weissman SM and Milstone LM: The core protein of epican, a heparan sulfate proteoglycan on keratinocytes, is an alternative form of CD44. J Invest Dermatol. 99:886–891. 1992. View Article : Google Scholar : PubMed/NCBI
29	Nishimura M, Yahagi N, Itoi T, Ochiai Y and Matsuda Y: A translational study to investigate the role of carbohydrate sulfotransferase 15 for pancreatic cancer biology from in vitro to first-in-human clinical research. J Clin Oncol. 33:e222012015.